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Abstract Matrix metalloproteases (MMPs) comprise a
family of enzymes that cleave protein substrates based on a
conserved mechanism involving activation of an active
site-bound water molecule by a Zn
2? ion. Although the
catalytic domain of MMPs is structurally highly similar,
there are many differences with respect to substrate spec-
iﬁcity, cellular and tissue localization, membrane binding
and regulation that make this a very versatile family of
enzymes with a multitude of physiological functions, many
of which are still not fully understood. Essentially, all
members of the MMP family have been linked to disease
development, notably to cancer metastasis, chronic
inﬂammation and the ensuing tissue damage as well as to
neurological disorders. This has stimulated a ﬂurry of
studies into MMP inhibitors as therapeutic agents, as well
as into measuring MMP levels as diagnostic or prognostic
markers. As with most protein families, deciphering the
function(s) of MMPs is difﬁcult, as they can modify many
proteins. Which of these reactions are physiologically or
pathophysiologically relevant is often not clear, although
studies on knockout animals, human genetic and epige-
netic, as well as biochemical studies using natural or syn-
thetic inhibitors have provided insight to a great extent. In
this review, we will give an overview of 23 members of the
human MMP family and describe functions, linkages to
disease and structural and mechanistic features. MMPs can
be grouped into soluble (including matrilysins) and
membrane-anchored species. We adhere to the ‘MMP
nomenclature’ and provide the reader with reference to the
many, often diverse, names for this enzyme family in the
introduction.
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Introduction
Metzincins are a ubiquitously expressed family of multi-
domain zinc (II)-dependent endopeptidases (Stocker and
Bode 1995), the members of which include well-known
metalloproteases such as the matrix metalloproteases
(MMPs) (Nagase and Woessner 1999), a disintegrin and
metalloproteases (ADAMs) (White 2003), the ADAMs
with a thrombospondin motif (ADAMTS) (Tang 2001), the
bacterial serralysins (Nakahama et al. 1986) and proteases
such as the astacins (including the meprins) (Bode et al.
1992; Butler et al. 1987). This superfamily of proteases is
deﬁned by the presence of a Zn
2? ion at the catalytic
center, which is coordinated by three histidine residues in
the zinc-binding consensus sequence HExxHxxGxxH that
is present in all proteolytically active metzincins, and a
characteristic, strictly conserved methionine-containing
tight 1,4 beta turn forming a hydrophobic cleft for the
catalytic zinc ion (Bode et al. 1993). Catalysis of protein
substrates is (most probably) carried out via a general base
mechanism involving activation of a zinc-bound water
molecule by the carboxylate group of the conserved glu-
tamate residue in the catalytic pocket followed by attack of
water on the polarized carbonyl group in the substrate’s
scissile bond (Browner et al. 1995).
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originally ascribed to the modulation and regulation of
extracellular matrix (ECM) turnover by direct proteolytic
degradation of the ECM proteins (e.g., collagen, proteo-
glycans and ﬁbronectin) (Woessner 1991). Another
important function is the liberation of biologically active
proteins such as cytokines, growth factors and chemokines
from their membrane-anchored proforms (so-called shed-
ding). More comprehensive ‘‘degradomics’’ approaches
indicate, however, that this view is likely too limited
(Butler and Overall 2009). MMPs thus contribute to the
generation of protein species with vastly differing activities
from a single, original gene product.
Matrix metalloproteases
Matrix metalloproteases or matrixins (see Table 1) are a
subfamily of metalloproteases, which consist of 23 distinct
proteases in humans (24 in mouse). The ﬁrst MMP was
identiﬁed in 1962 as the protease responsible for the deg-
radation of ﬁbrillar collagen in tadpole tails during meta-
morphosis and was thus dubbed interstitial collagenase
(Gross and Lapiere 1962). After identiﬁcation of a similar
collagenase in human skin, this protease was renamed
MMP-1. MMPs have since been identiﬁed as the major
enzymes responsible for turnover of extracellular matrix by
proteolytic degradation of virtually all proteinaceous
components of the ECM (Woessner 1991).
MMPs are largely excreted proteins with several con-
served domains (see Fig. 1). All MMPs contain the cata-
lytic domain, which is shielded off in the inactive form of
the enzyme by the prodomain. This propeptide interacts
with the catalytic region through a conserved cysteine
residue and the Zn
2? ion in the catalytic pocket (the so-
called cysteine switch) (Nagase 1997; Van Wart and
Birkedal-Hansen 1990). Except for MMP-7, MMP-23 and
MMP-26, all MMPs contain a C-terminal hemopexin-like
domain that functions primarily as a recognition sequence
for the substrate (Murphy and Knauper 1997). Although
MMPs retain catalytic activity toward a wide range of
substrates when missing this domain, the hemopexin
domain, which is structured like a four-bladed propeller
structure with each blade consisting of four antiparallel
b-sheets and one a-helix, is an absolute necessity for the
degradation of triple-helical collagens (Bode 1995). The
gelatinases (MMP-2 and -9) further contain a series of
three ﬁbronectin type II inserts in the catalytic domain,
which facilitate binding of gelatine and collagen (Bode
et al. 1999).
MMP function is regulated at several levels. Firstly,
induction of gene expression is controlled by number
growth factors and cytokines, and may be suppressed by
transforming growth factor b and glucocorticoids (Nagase
Table 1 Overview of the
23 identiﬁed human matrix
metalloproteases and their
common names
MMP Alternative name MMP Alternative name
1 Collagenase-1 16 Membrane type-3 MMP
Interstitial collagenase
2 Gelatinase A 17 Membrane type-4 MMP
72-kDa type IV collagenase
3 Stromelysin-1 19 None
Transin-1 Human ortholog of Xenopus MMP-18
7 Matrilysin 20 Enamelysin
Pump-1
8 Collagenase-2 21 None
Neutrophil collagenase Human ortholog of Xenopus xMMP
9 Gelatinase B 23 Cysteine array MMP
92-kDa type IV collagenase Femalysin
MMP-22
10 Stromelysin-2 24 Membrane type-5 MMP
11 Stromelysin-3 25 Membrane type-6 MMP
Leukolysin
12 Macrophage metallo-elastase 26 Matrilysin-2/endometase
13 Collagenase-3 27 None
14 Membrane type-1 MMP 28 Epilysin
15 Membrane type-2 MMP
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123and Woessner 1999; Vincenti 2001). Recent insights indi-
cate an important modulatory role of epigenetic processes
in the expression of MMPs (Chernov et al. 2009). Besides
soluble factors, MMP expression may also be regulated by
cell–cell contact or interaction of cells with ECM compo-
nents such as EMMPRIN (extracellular matrix metallo-
protease inducer or CD147) (Biswas et al. 1995). The
expressed MMPs are largely excreted as inactive proen-
zymes with the propeptide effectively limiting entrance
into and catalysis of a substrate in the catalytic pocket by
blocking the catalytic zinc (II) ion via the cysteine switch
mechanism. Activation of proMMPs can occur through
several mechanisms [reviewed in Ra and Parks (2007)], all
of which lead to disruption of the cysteine switch. Perhaps,
the most important mechanism is proteolytic removal of
the prodomain by other endopeptidases such as furin (Pei
and Weiss 1995). Removal of the prodomain of MMPs,
which contains a furin-like proprotein convertase recogni-
tion site (RRKR or RxKR), has been described for nine
MMPs including all membrane-type MMPs. Alternatively,
the prodomain can be proteolytically removed by plasmin
and other serine proteases, or even other MMPs. This
mechanism is well described for MMP-2 where proMMP-2
binds the endogenous MMP inhibitor TIMP-2 (tissue
inhibitor of metalloproteases 2). This complex in turn
functions as a ligand for the membrane-bound MMP-14 (or
membrane-type 1 MMP) leading to activation of MMP-2
(Cao et al. 1996).
The cysteine switch may also be broken by chemical
reactions, either physiologically by oxidation of cysteine
by reactive oxygen species, or artiﬁcially by mercury-
containing compounds such as 4-aminophenylmercuric
acetate (APMA) or denaturing surfactants such as sodium
dodecyl sulfate (SDS). This disruption of the thiol–zinc
interaction leads to allosteric relocation of the prodomain
leading to active forms of the enzyme with the propeptide
still attached or to autoproteolytic removal of the relocated
prodomain. MMPs are inhibited by the general protease
inhibitor a2-macroglobulin and a small family of natural
inhibitors speciﬁcally geared toward inhibiting metallo-
protease activity. These TIMPs are a group of four proteins
(21–30 kDa in size) that as a group effectively inhibit all
MMPs in vivo (Gomez et al. 1997).
Excreted MMPs are generally classiﬁed according to
their substrate speciﬁcity, leading to four classes: the col-
lagenases (MMP-1, -8 and -13), the gelatinases (MMP-2
and -9), the stromelysins (MMP-3, -10 and -11) and a
heterogeneous group containing matrilysin (MMP-7),
metallo-elastase (MMP-12), enamelysin (MMP-20), en-
dometase (MMP-26) and epilysin (MMP-28). In this
nomenclature, the membrane-anchored MMPs (MMP-14,
-15, -16, -17, -24 and -25) are considered as a separate class.
An alternate classiﬁcation arranges the MMPs according to
their domain structure (Sternlicht and Werb 2001).
Soluble MMPs: collagenases
MMP-1
MMP-1 or collagenase-1 was the ﬁrst described matrix
metalloprotease and has sparked a large volume of research
on the physiological and pathological role of MMPs.
MMP-1 is a secreted enzyme and contains the hemopexin-
like domain necessary for degradation of triple-helical
collagens. ProMMP-1 is probably activated via a two-step
proteolytic process involving either mast cell tryptase
(Gruber et al. 1989) or urokinase (Iba et al. 2000) and
MMP-3. Mature collagenase-1 can be found as two distinct
forms: a major 57-kDa species and a minor, glycosylated
61-kDa form (Pardo and Selman 2005). The active enzyme
is inhibited by TIMP-1.
MMP-1 has a wide substrate speciﬁcity and is capable of
degrading aggrecan, versican, perlecan, nidogen, serpins
and tenascin-C (McCawley and Matrisian 2001). Since
MMP-1 does contain the hemopexin domain, it is one of
the MMPs capable of proteolytic cleavage of ﬁbrillar col-
lagen leading to unwinding of the triple-helical structure
that leaves collagen (or gelatine) highly susceptible to
degradation by other proteases. Proteolysis by MMP-1 has
also been implicated in the release of membrane-anchored
proforms of insulin growth factor-binding proteins (IGFBP-3
and -5), IL-1b and L-selectin, among others (McCawley and
Matrisian 2001).
Since mice lack a clear ortholog of human MMP-1,
deﬁnition of the physiological role by creating knockout
mice has not been possible, but transgenic mice that
express human MMP-1 are known to develop lung
Fig. 1 Schematic representation of the domain structure of metzincin
proteases. A signal peptide, B prodomain, C catalytic domain,
D hemopexin-like domain, E ﬁbronectin type II insert, F transmem-
brane domain, G cytoplasmic tail, H disintegrin domain, I cysteine-
rich domain, J EGF-like domain, K thrombospondin type I-like
repeat, L spacer region
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123emphysema, indicating a possible role for MMP-1 in
development of this disease (D’Armiento et al. 1992).
Other experiments with transgenic mouse strains have
revealed development of skin disorders such as hyperker-
atosis and bone growth retardation (D’Armiento et al.
1995; Imai et al. 2007). Since MMP-1 appears to play a key
role in the turnover of ECM, deregulation of MMP-1
activity has been hypothesized to be involved in various
diseases related to excessive or insufﬁcient ECM turnover,
such as arthritis (Vincenti et al. 1994; Vincenti and
Brinckerhoff 2002), cancer (Benbow et al. 1999; Brinc-
kerhoff et al. 2000), wound healing disorders (Muller et al.
2008) and ﬁbrotic diseases (Iredale et al. 1998). MMP-1
expression has been reported to be sensitive to oxidative
stress (Alge-Priglinger et al. 2009) and cigarette smoke
exposure in an ERK -dependent mechanism (Mercer
et al. 2009). MMP-1 activity may be regulated by redox
mechanisms with low molecular weight thiols, such as
glutathione and (homo)cysteine, inactivating MMP-1 by
interaction with the catalytic Zn
2? ion and thus mimicking
the cysteine switch, an effect that can be abrogated by
oxidizing radicals (Koch et al. 2009).
Although many studies have found a positive correlation
between MMP-1 expression and disease, it has proven
difﬁcult to clearly identify MMP-1 as a systemic marker of
the investigated disease. A recent study identiﬁed the level
of circulating MMP-1 as a possible prognostic marker for
the plaque burden in atherosclerosis, but the authors were
unable to differentiate calciﬁed and non-calciﬁed plaques
based solely on MMP-1 levels in serum (Lehrke et al.
2009). Experiments with local sampling have proven more
accurate, for instance in the analysis of MMP-1 in synovial
ﬂuid of rheumatoid arthritis patients, where MMP-1 levels
correlated with inﬂammatory activity (Maeda et al. 1995;
Peake et al. 2005).
MMP-8
MMP-8 (neutrophil collagenase or collagenase-2) is very
similar to MMP-1 in structure and physiological function,
although subtle differences in substrate selectivity exist.
MMP-8 has a stronger afﬁnity toward type I collagen than
MMP-1, while MMP-1 preferentially cleaves type III col-
lagen (Balbin et al. 1998). Neutrophil collagenase was ﬁrst
described in 1990 when it was cloned from neutrophils
obtained from a patient with granulocytic leukemia (Hasty
et al. 1990). Contrary to MMP-1, MMP-8 is not released
immediately after synthesis, but rather stored in speciﬁc
granules that release the active enzyme on stimulation
(Schettler et al. 1991). As with MMP-1, MMP-8 can be
activated by proteolytic removal of the propeptide by
stromelysin-1 (MMP-3), but also by matrilysin (MMP-7)
(Dozier et al. 2006). The mature enzyme is 64 kDa in size,
with glycosylation increasing the size to 75 kDa. Auto-
proteolytic degradation has been described, yielding a
40-kDa fragment, which retains catalytic activity but does
not cleave ﬁbrillar collagen. MMP-8 activity can be
inhibited by TIMP-1 and TIMP-2 (Knauper et al. 1993).
MMP-8 seems to have an important function during
embryogenesis and postpartum remodeling of uterine tis-
sue, as demonstrated by expression studies in mice (Balbin
et al. 1998). MMP-8 has also been implicated as one of
the major contributors to connective tissue turnover in
inﬂammation due to oxidative auto-activation of the
enzyme (Weiss et al. 1985). Experimental evidence has
shown that puriﬁed MMP-8 is capable of degrading
a1-proteinase inhibitor, which might link increased MMP-8
activity to the pathology associated with pulmonary
emphysema (Desrochers et al. 1992). Experiments with
MMP-8 null mice demonstrate decreased migration of
polymorphonuclear leukocytes into the airway lumen in a
heterotopic airway transplant model, indicating a pivotal
role of the protease in the development of obliterative
bronchiolitis (Khatwa et al. 2010).
The role of MMP-8 in cancer is interesting, since recent
ﬁndings suggested this MMP to have a protective effect by
suppressing tumor metastasis (Gutierrez-Fernandez et al.
2008; Korpi et al. 2008) and by increasing the suscepti-
bility to oncolytic viruses (Mok et al. 2007). On the other
hand studies have identiﬁed MMP-8 as a promoter of
ovarian tumor proliferation (Stadlmann et al. 2003) and
high MMP-8 expression seems to be an indicator for poor
prognosis (Stenman et al. 2003). This contradicting evi-
dence of the role of MMP-8 in cancer is an indication of
the complex, and so far still poorly understood biological
roles of MMPs. MMP-8 is further involved in various
inﬂammatory processes, such as atherosclerosis, where
both expression as well as protease activity are higher in
vulnerable plaques than in stable plaques (Herman et al.
2001; Molloy et al. 2004), indicating that MMP-8 may be
useful as a marker for plaque instability in atherosclerosis.
MMP-13
MMP-13 (collagenase-3) is the latest human collagenase
described in literature. This enzyme exhibits preference
toward cleavage of type II collagen, effectively completing
the substrate spectrum of the collagenases. Collagenase-3
was ﬁrst cloned from breast cancer tissue in 1994 (Freije
et al. 1994). MMP-13 expression can be inﬂuenced by a
wide range of hormones and cytokines, such as parathyroid
hormone (indicative of the important role of MMP-13 in
bone development), insulin-like growth factors I and II,
platelet derived growth factor, basic ﬁbroblast growth
factor, transforming growth factor b1 (interestingly both
up- and downregulates MMP-13 expression depending on
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123the tissue), interleukin-1 and -6, tumor necrosis factor a
and many more (Leeman et al. 2002). ProMMP-13 can be
activated by auto-proteolysis or propeptide removal by
various other MMPs like stromelysin-1 (MMP-3), yielding
a mature enzyme of 48 kDa, which in turn can be inhibited
by TIMP-1, -2 and -3 (Knauper et al. 1996). Active MMP-
13 is a key factor in the activation pathway of several
MMPs. Besides the TIMP route of inactivation, MMP-13
can bind to a speciﬁc receptor on the surface of osteoblasts
and ﬁbroblasts resulting in internalization and degradation
of the protease (Barmina et al. 1999).
MMP-13 plays an important role in bone development
and remodeling, as may be anticipated from its capability
to cleave type II collagen (a major component of cartilage).
This rather speciﬁc function is reﬂected in a limited
expression proﬁle of MMP-13 during development and
adulthood, which is restricted to developing skeletal tissue.
MMP-13 has, contrary to the other collagenases, a rela-
tively high speciﬁc activity toward gelatine, indicating that
the proteolytic role of MMP-13 expands past the ﬁrst step
of cleavage of triple-helical collagens. Further identiﬁed
substrates of MMP-13 include aggrecan and perlecan,
transforming growth factor b, biglycan, the large protein
species of tenascin-C, ﬁbrillin-1 and -2, ﬁbrinogen and two
serpins (a2-antichymotrypsin and plasminogen activator
inhibitor-2) (Leeman et al. 2002).
MMP-13 expression has been regularly referred to in the
literature as indicative of various cancerous processes
including chondrosarcoma, breast cancer, head and neck
tumors and melanoma (Balbin et al. 1999). In all cases,
high expression of MMP-13 seems to be related to
aggressiveness of the tumor, and MMP-13 may even be
required for metastasis of certain tumors as demonstrated
for malignant melanoma (Zigrino et al. 2009).
Regarding the important role of MMP-13 in bone turn-
over, it is not surprising that this enzyme has been linked to
various bone-related diseases. Since MMP-13 degrades
both type II collagen and aggrecan, it has been linked to
cartilage destruction in rheumatoid and osteoarthritis
(Burrage et al. 2006). The specialized role of MMP-13 in
bone development and disease has made it an attractive
target for selective MMP-13 inhibitors as therapeutic
compounds (Heim-Riether et al. 2009; Hu et al. 2005;
Jungel et al. 2010; Leeuwenburgh et al. 2006).
Soluble MMPs: gelatinases
MMP-2
MMP-2 (gelatinase A, 72-kDa type IV collagenase) is one
of the two described human gelatinases in the MMP family,
named for their ability to proteolytically degrade gelatine
(denatured collagen). MMP-2 is ubiquitously expressed as
a 72-kDa proenzyme and subject to extensive glycosyla-
tion. Expression of MMP-2 is constitutive and most pro-
inﬂammatory stimuli fail to increase the expression level
since the gene, in contrast to that of MMP-9, lacks binding
sites for pro-inﬂammatory transcription factors such as
activator protein-1 (Templeton and Stetler-Stevenson
1991).
The MMP-2 proenzyme is activated by forming a
complex with TIMP-2 under appropriate stoichiometric
conditions, which in turn is a substrate for the membrane-
bound membrane type-1 MMP (MMP-14) that removes the
prodomain of proMMP-2 by proteolytic cleavage (aided by
free active MMP-2), yielding the truncated 64-kDa active
enzyme (Deryugina et al. 2001). If the concentration of
TIMP-2 is too high, both MMP-14 and active MMP-2 will
be inhibited, and no further activation will ensue. Besides
this activation pathway, proMMP-2 can also be activated
by thrombin and activated protein C (Nguyen et al. 2000).
MMP-2 differs from other MMPs in that the catalytic
domain contains cysteine-rich inserts that resemble the
collagen-binding regions of the type II repeats in ﬁbro-
nectin. These inserts are required for binding and cleavage
of collagen and elastin (Murphy et al. 1994). MMP-2 is
capable of cleaving gelatine, type I, IV and V collagens,
elastin and vitronectin (Chakrabarti and Patel 2005).
Through their ability to degrade collagen in the vascular
basal membranes, the gelatinases are involved in neovas-
cularization (Nguyen et al. 2001) both under physiological
conditions and in pathologies such as tumor metastasis.
The state of activation seems to be of crucial importance
for the function of MMP-2 in angiogenesis. Recent
research has demonstrated that the fully mature active form
induces apoptosis in endothelial cells and inhibits neovas-
cularization, while an intermediate activated form in
complex with MMP-14 enhances cell survival and pro-
motes angiogenesis (Shapiro et al. 2010).
MMP-2 can also facilitate migration of cells by direct
degradation of the basement membrane thus allowing
inﬁltration of, for instance, neutrophils and lymphocytes, or
liberation of chemoattractants (Nagase 1998). This latter
process, named ‘ectodomain shedding’, is an important
physiological function of the membrane-bound ADAM
proteases, but has also been described for many other
members of the metzincin superfamily. MMP-2 has been
known to be involved in both promoting and inhibiting
inﬂammation by liberation of pro-inﬂammatory mediators
[for instance the active form of interleukin-1b (Schonbeck
et al. 1998)], proteolytic degradation of chemoattractants
[for instance, transforming monocyte chemoattractant
protein-3 into the truncated form with antagonistic prop-
erties on the CC chemokine receptor (McQuibban et al.
2002)] and a profound role in the chemotactic gradient that
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123is necessary in the clearance of inﬂammatory cells from
tissue (Corry et al. 2002). Recent evidence from proteo-
mics studies shows that the role of MMP-2 in processing
signaling proteins may be much greater than originally
anticipated, which, if conﬁrmed for other MMPs, could
lead to a paradigm shift in the physiological role of these
proteases (Dean et al. 2007; Dean and Overall 2007).
Interestingly, MMP-2 knockout mice exhibit a normal
phenotype under physiological conditions, although the
animals do show different response patterns upon allergen
challenge, which may be attributed to disturbance of the
important role of clearing immune cells (Corry et al. 2002).
These ﬁndings indicate that MMP-2 function may be
interchangeable with other metalloproteases, a hypothesis
that is supported by the observation that expression of the
second gelatinase, MMP-9, is greatly increased in MMP-2
null mice (Esparza et al. 2004).
MMP-9
MMP-9 (gelatinase B, 92-kDa type IV collagenase) was
ﬁrst discovered in neutrophils in 1974 (Sopata and
Dancewicz 1974). MMP-9 is expressed as a 92-kDa pro-
enzyme, which can be activated to the 83-kDa mature
enzyme. The larger size of MMP-9 relative to MMP-2 can
be attributed to a heavily O-glycosylated collagen V-like
insert that links the metalloprotease domain to the hemo-
pexin-like domain (Mattu et al. 2000). MMP-9 activation
may be mediated by removal of the prodomain by serine
proteases or other MMPs (Ogata et al. 1992), or may be a
direct response to oxidative stress that disrupts the cysteine
switch (Maeda et al. 1998). While a considerable overlap
exists in the substrates degraded by MMP-2 and -9, MMP-9
is incapable of direct proteolysis of collagen I (Chakrabarti
and Patel 2005).
MMP-9 has been described to release the biologically
active form of vascular endothelial growth factor (VEGF),
which plays an important role in angiogenesis. This process
is complemented by the direct proteolytic degradation of
vascular basement membrane proteins, indicating that
MMP-9 (even more than MMP-2) may play a crucial role
in the formation of new blood vessels (Bergers et al. 2000).
Interestingly, the hemopexin domain of MMP-9 was
reported to be an inhibiting factor in angiogenesis as
demonstrated by decreased invasion of glioblastoma cells
overexpressing the MMP-9 hemopexin domain in a xeno-
graft model (Ezhilarasan et al. 2009).
MMP-9 plays an important role in migration of immune
cells as demonstrated by the reduced presence of neutro-
phils, lymphocytes and dendritic cells in brochoalveolar
lavage ﬂuid (BALF) of MMP-9 knockout mice after anti-
gen challenge (Lemjabbar et al. 1999). MMP-9 null mice
show decreased fertility, since MMP-9 is crucial during
several stages of the female reproductive cycle (implanta-
tion of the embryo and remodeling of endometrial tissue
that occurs during the menstrual cycle) (Dubois et al.
2000). Absence of MMP-9 also leads to disorders in bone
development, speciﬁcally delayed bone ossiﬁcation due to
insufﬁcient angiogenesis in growth plates (Vu et al. 1998)
and reduced osteoclast recruitment (Engsig et al. 2000).
The biological roles of MMP-9 have been extensively
reviewed in (Van den Steen et al. 2002).
MMP-9 is capable of processing cytokines and chemo-
kines similarly to MMP-2. MMP-9 cleaves interleukin-8 to
its more potent truncated form, activates IL-1b and trans-
forming growth factor b (Chakrabarti and Patel 2005).
Proteomics techniques revealed a role of active MMP-9 in
shedding b2 integrin from macrophages (Vaisar et al.
2009). Whereas MMP-2 is primarily inhibited by TIMP-2,
MMP-9 is mostly inhibited by TIMP-1 (Crocker et al.
2004). Contrary to MMP-2, which is expressed ubiqui-
tously under physiological conditions, MMP-9 is only
present constitutively in neutrophils (Devarajan et al.
1992), where it is stored in granules to be rapidly released
after stimulation. Expression in many other cell types is
inducible by (inﬂammatory) stimuli (Opdenakker et al.
1991), is increased in malignant cell lines and correlates
with their metastatic potential (Baruch et al. 2001). Neu-
trophil-derived MMP-9 is distinguishable from other
sources since it forms a covalent complex with neutrophil
gelatinase B-associated lipocalin (NGAL) (Kjeldsen et al.
1993).
The role of gelatinases in pathology has been studied
extensively, especially in lung diseases [reviewed in
Chakrabarti and Patel (2005)] and cancer [reviewed in e.g.
Bjorklund and Koivunen (2005) and Klein et al. (2004)].
The amount of both gelatinases in BALF and sputum of
patients suffering from chronic asthma is higher than in
healthy individuals and this increase is hypothesized to be
mainly due to gelatinases originating from eosinophils,
neutrophils and epithelial cells (Maisi et al. 2002; Mautino
et al. 1997). This increase may be responsible for the
characteristic tissue remodeling events observed in chronic
asthma such as thickening of the basement membrane,
smooth muscle tissue hypertrophy and reduced epithelial
thickness. MMP-2 does not seem to play an important role
in the pathophysiology of acute asthma, but MMP-9 and
the MMP-9/TIMP-1 ratio are increased in exacerbations of
acute asthma (Lemjabbar et al. 1999). This phenomenon
may be explained by the presence of a pool of MMP-9
inside inﬁltrating neutrophils that is released during the
asthmatic attack. Since neutrophils do not produce TIMP-
1, degranulation leads to a strong increase in the local
concentration of proteolytically active MMP-9, which
may cause several of the symptoms observed in acute
asthma, such as airway obstruction due to desquamation of
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123epithelial cells and increased mucus production by goblet
cells (Chakrabarti and Patel 2005).
The role of gelatinases in the pathophysiology of
chronic obstructive pulmonary disease (COPD) has not
been clearly established, but excess protease activity plays
an important role in the development and progression of
the disease. Sputum and BALF of patients contain elevated
concentrations of both MMP-2 and -9. MMP-9 may be an
important factor in COPD development, since MMP-9
activity not only causes ECM destruction but has also been
described to degrade a1-protease inhibitor leading to
increased activity of neutrophil elastase and cathepsin G
(Chakrabarti and Patel 2005; Liu et al. 2000). MMP-9 is
further capable of promoting inﬁltration of neutrophils
(loaded with MMP-9-containing granules) by production of
the biologically more active truncated form of IL-8, caus-
ing a vicious circle of MMP-9 activity in the diseased lung.
Presence and activity of gelatinases is elevated in many
other pulmonary diseases, such as cystic ﬁbrosis, bron-
chiectasis, acute respiratory distress syndrome (ARDS) and
infections [reviewed in Chakrabarti and Patel (2005) and
Van den Steen et al. (2002)].
Gelatinases in cancer pathology
The obvious relation of gelatinases to tumor metastasis and
angiogenesis has led to a plethora of research papers on the
role of MMP-2 and -9 in diverse malignant processes. This
hypothesis was ﬁrst afﬁrmed by the observation that MMP-
2 knockout mice show decreased tumor angiogenesis and
progression (Itoh et al. 1998). Since then, MMPs have been
identiﬁed as important players in angiogenesis, growth and
metastasis of tumors.
The development of a new vascular system is necessary
for tumor growth, since without new blood vessels the size
of a tumor will be restricted. Gelatinases are primarily
involved in this process by enabling proteolytic degrada-
tion of the vascular basal membrane, opening the way for
migration of endothelial cells to form new blood vessels
(Risau 1997). MMP-2 is further capable of cleaving lami-
nin-5, which after degradation yields a cryptic site that
increases endothelial cell migration (Risau 1997) and the
release of VEGF that stimulates angiogenesis, not only
under physiological conditions but also during tumor
development. Tumor growth can be stimulated by gela-
tinase activity, since MMP-2 and -9 have been shown to
release growth factors (Levi et al. 1996). Tumor metastasis
is a process that involves the release of single tumor cells,
migration of these cells to a blood vessel, penetration into
the blood stream or lymph system and ﬁnally adhesion to
vessel endothelium and extravasation into the tissue at the
metastatic location. The ECM degrading properties of
gelatinases are crucial in both exit of the metastatic cells
from the bulk tumor as well as their entrance at the site of
metastasis.
Increased gelatinase expression and activity has been
described in hundreds of publications related to malignant
diseases ranging from breast cancer (Somiari et al. 2006),
urogenital cancers (Maatta et al. 2007; Sier et al. 2000;
Takemura et al. 1992), brain tumors (Forsyth et al. 1999),
lung cancer (Nawrocki et al. 1997), skin cancer (Pyke et al.
1992), colorectal cancer (Murnane et al. 2009) and many
more. Interestingly, many authors have found a positive
correlation between gelatinase expression or activity and
the invasive potential of the tumor, again stressing the
crucial role that MMP-2 and -9 play in metastasis.
A comprehensive review of the literature on the role of
gelatinases in individual cancers is beyond the scope of this
article, but excellent reviews are available (Van den Steen
et al. 2002).
Besides in pulmonology and oncology, gelatinase
activity is under investigation in several other research
ﬁelds. MMP-2 has, for example, been identiﬁed as a pos-
sible target in cardiovascular disease, since it was identiﬁed
as the protease responsible for degradation of the vasodi-
lator peptide andrenomedullin, with one of the resulting
fragment peptides having vasoconstrictive properties,
possibly leading to hypertension (Martinez et al. 2004).
Soluble MMPs: stromelysins
MMP-3
MMP-3 or stromelysin-1 was ﬁrst described in 1985 as a
51-kDa protein secreted by rabbit ﬁbroblasts (Chin et al.
1985). MMP-3 could be distinguished from collagenases
by the inability to degrade type I collagen. More or less
simultaneously, a protease named transin was described in
transformed rat cells, which later was identiﬁed to corre-
spond to MMP-3 (Matrisian et al. 1985, 1986). Stromelysins
have a basic MMP structure, with a hemopexin-like domain.
The 51-kDa latent proenzyme can be activated by proteo-
lytic removal of the prodomain by, for instance, the serine
proteases trypsin-2 (Moilanen et al. 2003) and matriptase
(Jin et al. 2006), yielding a 43-kDa active enzyme in
humans. MMP-3 is upregulated on exposure to interleukin
1b and downregulated by retinoic acid and dexamethasone
(Saus et al. 1988).
The substrate speciﬁcity of MMP-3 is broad and MMP-3
has been described to degrade many ECM proteins such as
ﬁbronectin, denatured collagens (gelatin), laminin and
proteoglycans. MMP-3 is incapable of degrading triple-
helical collagens, but can cleave the globular portion of
type IV collagen (McDonnell and Matrisian 1990). Besides
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in the activation cascade of the gelatinases and MMP-13.
The physiological function of MMP-3 is, surprisingly, not
well described in literature, but is assumed to be mainly
related to the turnover of extracellular matrix. MMP-3 is
highly upregulated in mammary tissue during involution
after the lactation period and seems to have a pro-apoptotic
effect (Witty et al. 1995).
In vitro experiments with cultured cells have identiﬁed
a few membrane-bound signaling proteins that may be
released by MMP-3 [e.g., E-cadherin (Lochter et al. 1997)
and Fas ligand (Matsuno et al. 2001)], but the physiological
relevance of these ﬁndings is unclear. One well-described
substrate of MMP-3 is plasminogen activator inhibitor-1
(PAI-1) (Lijnen et al. 2000). ProMMP-3 can also form a
complex with tissue-type plasminogen activator, which
increases the activity of t-PA (Arza et al. 2000). These
ﬁndings may be indicative of an important regulatory
function of MMP-3 in the ﬁbrinolytic pathway.
MMP-3 has been described as an important factor in the
development ofarthritis (Green etal. 2003),asthma(Dahlen
et al. 1999), aneurism (Silence et al. 2001), impaired wound
healing (Fray et al. 2003), Alzheimer’s disease (Yoshiyama
et al. 2000) and various cancers (Mercapide et al. 2003;
Wiesen and Werb 1996). Recent insights and studies dem-
onstrate that association of MMP-3 with disease states
(especially cancer) is uncertain, as many newer studies do
not ﬁnd a positive correlation between MMP-3 and disease.
Thisobservationmaybe(partially)explainedbythefunction
of MMP-3 as an activator of other MMPs, which makes
identiﬁcation of the protease ‘culprit’ difﬁcult.
MMP-10
The cloning of rat transin/MMP-3 in 1985 quickly led to
the identiﬁcation of a second stromelysin. This protease,
named transin-2 (Breathnach et al. 1987), and later iden-
tiﬁed in humans as stromelysin-2 (Muller et al. 1988)o r
MMP-10, has 82% sequence homology with MMP-3
(Sirum and Brinckerhoff 1989). MMP-10 is secreted as a
53-kDa proenzyme and is activated to a 47-kDa mature
protease. Originally, MMP-10 production was thought to
be relatively unaffected by stimuli such as cytokines and
hormones (Brinckerhoff et al. 1992), but recent studies
have shown results that indicate the contrary (Barksby
et al. 2006).
The physiological function of MMP-10 is poorly
understood, with only a handful of publications dealing
with characterization of this protease. The in vitro substrate
speciﬁcity seems similar to that of MMP-3, but catalytic
activity toward type III, IV and V collagens is weaker
(Murphy et al. 1991). Contrary to MMP-3, MMP-10 is not
produced by ﬁbroblasts, but is expressed in keratinocytes
which in turn do not produce MMP-3 (Saarialho-Kere et al.
1994). MMP-10 seems to have an important role in skin
wound healing and cellular migration, since it is primarily
found at the front of the migrating epithelial ‘tongue’
(Madlener and Werner 1997) and has been observed in
migrating enterocytes in inﬂammatory bowel disease
(Salmela et al. 2004; Vaalamo et al. 1998). MMP-10 is, in
vitro, capable of processing laminin-5, which may be an
additional mechanism by which the enzyme enables cel-
lular migration (Krampert et al. 2004). MMP-10 presence
and activity at sites of resorption in developing bone have
been demonstrated by histochemistry and casein in situ
zymography and may play a role in remodeling events
taking place during ossiﬁcation (Bord et al. 1998).
MMP-11
The third human stromelysin is MMP-11, which was ﬁrst
described in 1990 in a breast carcinoma cDNA library
(Basset et al. 1990). Although MMP-11 is often catego-
rized as a stromelysin, it is very different from the other
two proteases in this group. Production of MMP-11 is
highest in ﬁbroblasts and is particularly pronounced in
remodeling tissues during the later stages of the process.
MMP-11 has been associated with many physiological
processes where ECM remodeling occurs, such as during
embryonic development, the female reproductive cycle
and wound healing. The 56-kDa MMP-11 proenzyme is
activated intracellularly by furin (Pei and Weiss 1995)o r
by paired basic amino acid cleaving enzyme-4 (PACE-4)
(Bassi et al. 2000) and is secreted as a 47-kDa active
protease. The physiological role of MMP-11 is unclear,
but differs signiﬁcantly from other MMPs. No major
ECM proteins such as collagens, gelatin and ﬁbronectin
can be degraded by MMP-11, and contrary to many other
MMPs, it exhibits an anti-apoptotic effect. The biological
mechanism underlying this effect is not known, but
probably involves proteolytic cleavage of yet uncharac-
terized protein substrates that promote cell survival
(Matziari et al. 2007). Several possible substrates of
MMP-11 have been identiﬁed, mainly protease inhibitors
such as a1 proteinase inhibitor and a2 macroglobulin.
MMP-11 further has a weak caseinolytic activity and has
been shown to cleave insulin-like growth factor-binding
protein-1 (IGF-BP-1) in a carcinoma cell line (Pei et al.
1994). Recent research has demonstrated that, although
MMP-11 does not cleave many ECM proteins, degrada-
tion of type VI collagen is one of its physiological
functions that is related to inhibition of adipogenesis
(Motrescu et al. 2008).
The relatively narrow and peculiar substrate speciﬁcity
of MMP-11 probably stems from a mutation that occurred
in the highly conserved methionine turn. Whereas all other
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proline is replaced by an alanine in MMP-11. This sub-
stitution has a profound effect on the structure of the S’1
selectivity pocket leading to greatly changed substrate
speciﬁcity (Noel et al. 1995).
Although the physiological role of MMP-11 is still
poorly understood, the involvement of this enzyme in
especially the early stages of the process of tumor forma-
tion and metastasis has been thoroughly investigated
[reviewed in Rio (2005)]. MMP-11 is rarely present in
sarcoma tumors, but almost always expressed in carcino-
mas. An interesting observation is that MMP-11 is not
produced by the malignant cells themselves, but by the
surrounding mesenchymal cells. High levels of MMP-11
have predictive value for tumor aggressiveness and low
survival rate. MMP-11 plays a role in early invasion of the
surrounding tissue by tumor cells, a process that is
dependent on the catalytic activity of the protease (Noel
et al. 2000). This is surprising since MMP-11 is not capable
of degradation of the major ECM constituents. Cancer cells
are able to stimulate nearby ﬁbroblasts to produce MMP-
11, a process that is associated with modiﬁcation of the
invaded ECM to a stroma phenotype by desmoplasia (Mari
et al. 1998). The anti-apoptotic effect of MMP-11 may play
a role in establishment of the tumor and early survival.
MMP-11-deﬁcient tumors exhibit higher levels of apopto-
sis, and implantation of experimental tumors is lower in
MMP-11 null mice (Boulay et al. 2001). Although devel-
opment of primary tumors is favorably affected by high
MMP-11 levels, the metastatic potential of MMP-11
expressing tumors seems to be lower. In experiments with
MMP-11 null mice, the number and size of secondary
tumors was greater than in wild-type mice implanted with
similar sized tumors, indicating a protective effect of
MMP-11 (Rio 2005).
Membrane-anchored MMPs: membrane-type MMPs
In addition to the soluble matrix metalloproteases, a small
group of membrane-anchored MMPs has been described.
The ﬁrst member of this subfamily, MMP-14 or membrane
type-1 MMP (MT1-MMP), was discovered in 1994 (Sato
et al. 1994) and cloning experiments have since revealed
the existence of ﬁve additional MT-MMPs. The domain
structure of MMP-14 is very similar to that of soluble
MMPs (see Fig. 1) with the characteristic zinc-binding
catalytic domain, the prodomain in the inactive proenzyme
and a linked hemopexin-like domain. Most MT-MMPs are
membrane anchored by a single-pass transmembrane
domain followed by an intracellular cytoplasmic tail that
contains three putative phosphorylation sites and is pre-
sumed to be important for localizing the enzyme on the cell
surface (Lehti et al. 2000). All MT-MMPs described con-
tain the furin-like recognition site in their prodomain,
allowing activation of the proenzyme by proteolytic
removal of this domain by furin and other proprotein
convertases (Yana and Weiss 2000).
MMP-14
MMP-14 is present at the cell surface as a 55–60 kDa
active protease, but may be processed by autocatalysis into
smaller species of 45 kDa by proteolytic removal of the
catalytic domain. This truncated form, which still contains
the hemopexin-like domain, is assumed to play a role in
autoregulation of MMP-14 catalytic activity (Toth et al.
2002). The substrate speciﬁcity of MMP-14 is well
described in literature [reviewed in Barbolina and Stack
(2008)]. The enzyme is capable of proteolytic degradation
of type I, II and III collagens following the characteristic
cleavage pathway used by collagenases (d’Ortho et al.
1997), a ﬁnding that was corroborated by knockout
experiments that conﬁrmed the role of MMP-14 as an
important interstitial collagenase. MMP-14 null mice die
within 3 weeks, showing severe developmental abnormal-
ities related to deﬁciencies in ECM processing, such as
dwarﬁsm, skeletal dysplasia and defective vascularization
(Holmbeck et al. 1999; Zhou et al. 2000). Expression of
MMP-14 may be regulated by the interaction of migrating
cells with a three-dimensional collagen matrix, which trig-
gers clustering of cell surface integrins and lead to tran-
scriptional activation of the MMP-14 promotor (Ellerbroek
et al. 2001). Besides collagen, MMP-14 is capable of
degradation of many other ECM components, such as
ﬁbronectin, vitronectin, tenascin, nidogen, aggrecan, ﬁbrin,
ﬁbrinogen and laminin-5, leading to a possible stimulation
of cellular migration as described above (Barbolina and
Stack 2008). Although the major proteolytic function of
MMP-14 lies in the cleavage of extracellular substrates,
some studies indicate a role in intracellular proteolysis after
incorporation and accumulation of active MMP-14 in the
centrosomal compartment, where it could contribute to
development of mitotic spindle changes by degradation of
pericentrin (Golubkov et al. 2005a, b). This mechanism
could give rise to a role for MMP-14 in malignant trans-
formation of cells. Intracellular protein–protein interaction
between MMP-14 and adenosine nucleotide translocator
has been described and is independent of the catalytic
activity of MMP-14. This observation may implicate
MMP-14 as a player in the regulation of the changing
energy metabolism in malignant cells during tumor for-
mation and migration (Radichev et al. 2009). MMP-14 has
further been identiﬁed as a cell surface sheddase and is
capable of cleavage of many membrane-anchored proteins
such as E- and N cadherin, integrins, hyaluronan receptor
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several cell surface proteoglycans and their receptors
(Barbolina and Stack 2008). Ongoing research by proteo-
mics techniques has revealed an ever-growing array of
possible endogenous substrates of MMP-14 (Niiya et al.
2009).
MMP-14 was originally identiﬁed as the extracellular
protease responsible for activation of proMMP-2, and this
process remains the best-described proteolytic function of
the enzyme. In this process, one of the units of an MMP-14
dimer forms a trimeric complex with proMMP-2 and
TIMP-2 at the cell surface leading to proteolytic removal of
the propeptide of the proMMP-2 by the ‘free’ MMP-14
unit. Besides proMMP-2, also proMMP-13 (Knauper et al.
2002) and proMMP-8 (Holopainen et al. 2003) have been
identiﬁed as possible targets for activation through this
mechanism.
The role of MMP-14 in angiogenesis is well described
and demonstrated by insufﬁcient vascularization in
knockout mice. MMP-14 is capable of degradation of the
deposited ﬁbrin matrix after vascular injury, effectively
disrupting the repair mechanism and allowing endothelial
cell invasion (Hiraoka et al. 1998). MMP-14 may also be
involved in migration of endothelial cells into the ECM, by
proteolytic degradation of extracellular matrix proteins and
by processing of various adhesion molecules (Galvez et al.
2001). The formation and stabilization of the newly formed
capillary tubes may also be dependent on MMP-14 activity,
as demonstrated by impaired capillary formation in
knockout models and RNA interference experiments
(Robinet et al. 2005). Finally, MMP-14 is able to release
vascular endothelial growth factor A (VEGF-A) by shed-
ding, again promoting neovascularization (Sounni et al.
2004). MMP-14 together with MMP-15 may even be the
determining factor in transforming cancer cells into the
invasive phenotype, a process that is regulated by zinc-
ﬁnger proteins such as Snail-1 (Ota et al. 2009).
MMP-15
MT2-MMP (MMP-15) was ﬁrst described in 1995 as the
second member of the membrane-anchored MMP sub-
family (Takino et al. 1995). MMP-15 is a ubiquitously
expressed enzyme with largely overlapping substrate
speciﬁcity with MMP-14 (d’Ortho et al. 1997). Although
the physiological function of this protease is not as well
described as for MMP-14, some studies have indicated a
role in follicle rupture during ovulation (Ogiwara et al.
2005) and the generation of tubular structures during
angiogenesis (Laﬂeur et al. 2002). MMP-15 has also anti-
apoptotic properties (Abraham et al. 2005). MMP-15 is
capable of activating the MMP-2 proenzyme, but contrary
to MMP-14 the activation mechanism is not dependent on
the presence of TIMP-2, but rather on interaction with the
hemopexin-like domain of MMP-2 (Morrison et al. 2001).
Involvement of MMP-15 in pathology is still unclear, but
considering the similarity with MMP-14 a role in cancer is
expected. Indeed, MMP-15 is present in many investigated
tumors, such as glioblastoma (Zhang et al. 2005), non-small
cell lung carcinoma (Atkinson et al. 2007), and ovarian
(Davidson et al. 2001) and breast carcinoma (Ueno et al.
1997), and seems to correlate with tumor invasiveness
(Zhang et al. 2005).
MMP-16 and MMP-24
The two latest additions to the membrane-spanning MMP
family are MT3-MMP (MMP-16), ﬁrst described in 1997
(Matsumoto et al. 1997), and MT5-MMP (MMP-24), ﬁrst
described in 1999 (Llano et al. 1999). These enzymes are
still poorly described in literature. The crystal structure of
MMP-16 has been elucidated, and shows extensive simi-
larity to MMP-14 (Lang et al. 2004). MMP-16 activity is
regulated by an autoproteolytic shedding process where a
soluble form of the enzyme is released from the cell sur-
face. The active enzyme shows high afﬁnity to TIMP-3, as
opposed to TIMP-1. Although originally anticipated to be a
brain-speciﬁc enzyme (Pei 1999a), MMP-24 is possibly
involved in remodeling events in endometrial lesions
and endometriosis (Gaetje et al. 2007). Like the other
MT-MMPs, bothMMP-16 and MMP-24 are capable of acti-
vating proMMP-2 (Wang et al. 1999a; Zhao et al. 2004).
MMP-17 and MMP-25
The ﬁnal two MT-MMPs are structurally different from the
other four with respect to their interaction with the cell
membrane. MT4-MMP (MMP-17) (Pendas et al. 1997)
and MT6-MMP (MMP-25) (Pei 1999b) are linked to the
cell membrane via a glycosyl-phosphatidyl-inositol (GPI)
anchor, as opposed to containing a membrane-spanning
domain. This anchor moiety is linked to the hemopexin-
like domain by a 35–45 amino acid long hydrophilic linker,
or stem. After production of the enzyme, this stem region is
linked to a short hydrophobic tail, which is exchanged for a
GPI anchor in the endoplasmic reticulum (Sohail et al.
2008). The stem region further contains two or three cys-
teine residues, which may have a function in formation
of dimers or trimers, as demonstrated by the presence
of *120 and *180-kDa protein species of MMP-25 that
are dissociated into the mature 57-kDa form of the enzyme
under reducing conditions (Sun et al. 2007). The GPI
anchor gives these enzymes the possibility of interaction
with lipid raft microstructures and may be involved in
internalization and recycling of the enzymes (Sohail et al.
2008). The TIMP-inhibition proﬁle of the GPI-anchored
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MT-MMPs. While the latter are relatively resistant to inhi-
bition by TIMP-1 due to incompatibility of the Thr
98 residue
with the S’1 selectivity pocket, MMP-17 and MMP-25 are
effectively inhibited by TIMP-1, as well as by TIMP-2
and TIMP-3 (English et al. 2001;W a n ge ta l .1999b).
GPI-anchored MT-MMPs can be shed from various cells in
exosomes, possibly leading to paracrine transfer to other
cells (Itoh et al. 1999).
Both MMP-17 and MMP-25 are capable of degrading
ECM proteins, albeit MMP-17 in a limited fashion with
cleavage demonstrated for gelatin, ﬁbrin and ﬁbrinogen.
MMP-25 can cleave a wider range of ECM constituents
including ﬁbronectin, type IV collagen and proteoglycans
(Kang et al. 2001). In vitro experiments have revealed a
multitude of possible substrates (including TNF alpha,
indicating sheddase activity), but the physiological rele-
vance is unclear [reviewed in Sohail et al. (2008)]. Inter-
estingly, MMP-17 is not able to activate proMMP-2 even
in vitro, making this the only MT-MMP that lacks this trait
(English et al. 2000). MMP-25 does activate proMMP-2,
but generates a different form of the active enzyme than the
other MT-MMPs, indicating that the interaction between
MMP-2 and MMP-25 is different (Nie and Pei 2003). This
activation mechanism is possibly dependent on the tight
junction protein claudin-5, since cells that do not produce
this protein are incapable of proMMP-2 activation by
MMP-25 (Miyamori et al. 2001). MMP-17 has been
described as an activator of the aggrecanase ADAMTS-4
(Gao et al. 2004).
Both GPI-anchored MT-MMPs are highly expressed in a
wide variety of cancer cells ranging from breast carcinoma
to glioma and colon cancers [reviewed in Sohail et al.
(2008)], but the clinical relevance of the presence of these
proteins in malignant cells is not yet clear.
Soluble MMPs: matrilysins
MMP-7
MMP-7 (matrilysin) was originally described as PUMP-1
(putative uterine metalloprotease-1) in 1988, and was long
considered a third member of the stromelysin family
(MMP-11 was not yet known), although it appeared only
distantly related to the other stromelysins (Muller et al.
1988). The pump-1 gene identiﬁed from rat tumor cDNA
cloning experiments was conﬁrmed to code for a secreted
metalloprotease in rat uterus (Woessner and Taplin 1988),
and later dubbed MMP-7. The mmp-7 gene contains a AP-1
promotor region, making it sensitive to upregulation by
cytokines and growth factors (Gaire et al. 1994). MMP-7 is
the smallest human MMP (28-kDa proenzyme, 19-kDa
mature active form), since it lacks the C-terminal hemo-
pexin-like domain. This ‘minimal domain structure’ means
that the activated enzyme comprises only the zinc-binding
catalytic domain and results in an inability of MMP-7 to
degrade intact collagens, again demonstrating the impor-
tance of the hemopexin-like domain in substrate recognition
(Quantin et al. 1989). MMP-7 is, however, capable of
degrading a wide array of other ECM components such as
gelatin, ﬁbronectin, laminin and elastin. MMP-7 is capable
of cleaving the prodomain of the gelatinases MMP-2 and -9
(Wilson and Matrisian 1996), but its relevance under phys-
iological conditions seems debatable considering the alter-
native, well-described activation pathway of proMMP-2.
Finally, MMP-7 is a possible sheddase, with potential to
liberate TNFa, Fas ligand, heparin-binding epidermal
growth factor (HB-EGF), E-cadherin and b4-integrin
(Ii et al. 2006).
The originally described biological function of MMP-7
is the involvement in involution of the endometrium after
pregnancy, but as later discovered, a unique function of
MMP-7 seems to be its role in innate immunity. MMP-7
knockout mice exhibit decreased resistance to bacterial
gastrointestinal infection and show decreased clearance of
E. coli from the small intestine. MMP-7 is constitutively
produced in the mucosal epithelium and may exert its
function in mice by cleavage of pro-a-defensins yielding
peptides with antibacterial properties. Co-localization of
MMP-7 and pro-a-defensins in specialized epithelial
Paneth cells seems to conﬁrm this function (Wilson et al.
1999). The role in mucosal host defense is further sup-
ported by the ﬁnding that exposure of cultured mucosal
epithelial tissue or cells to pathogenic bacteria such as
E. coli or Pseudomonas aeruginosa causes an increased
production of MMP-7, and that germ-free bred mice show
no expression of MMP-7 in the unchallenged gastro-intes-
tinal tract (Lopez-Boado et al. 2001). The strong induction
of MMP-7 by bacterial challenge is an epithelium-speciﬁc
function, since it does not occur in other cell types
expressing MMP-7, and is exclusive for MMP-7 since no
other MMPs are upregulated (Parks and Shapiro 2001).
MMP-7 seems to be important in wound repair, since
MMP-7 null mice show severe defects in epithelial
wound healing which is probably due to a disrupted re-
epithelialization (Dunsmore et al. 1998). MMP-7 further
enables migration of neutrophils through the epithelium
during inﬂammation, since MMP-7 null mice show accu-
mulation of neutrophils in the interstitium without them
crossing over into the epithelium (Li et al. 2002). The
mechanism underlying this effect is probably the creation
of a chemotactic gradient for neutrophils by cleavage of the
proteoglycan syndecan-1 at the epithelial cell surface,
causing liberation of the syndecan-bound chemokine KC
that is produced by the epithelial cells after injury.
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MMP-7 seems to occupy a unique place among MMPs
with respect to cancer association, since it is one of the few
MMPs that is actually produced by cancerous cells them-
selves, as opposed to the stroma-derived MMPs that are
produced under stimulation by malignant cells (Ii et al.
2006). As with other MMPs, MMP-7 has been identiﬁed in
a wide range of tumors, and correlates with the aggres-
siveness of the tumor. In a malignant state, the activation of
MMP-2 and -9 by MMP-7 may have an important function,
and lead to increased invasiveness (Wang et al. 2005,
2006). MMP-7, like MMP-3 may further promote tumor
invasion by shedding of E-cadherin, leading to decreased
cellular adhesion. Tumor growth is likely associated with
MMP-7 sheddase activity, since the release of soluble HB-
EGF by MMP-7 promotes cellular proliferation (Yu et al.
2002). MMP-7 is further capable of cleaving all six
members of the insulin-like growth factor-binding protein
(IGF-BP) family, leading to increased availability of free
IGF, which again promotes cancer cell growth and survival
(Nakamura et al. 2005). The activation of ADAM-28 is
also attributed to MMP-7 (Mochizuki et al. 2004), leading
to increased degradation of IGF-BP3.
MMP-26
Recently, a novel matrilysin-like enzyme was identiﬁed in
an endometrial tumor and named MMP-26 (matrilysin-2,
endometase) (de Coignac et al. 2000; Uria and Lopez-Otin
2000). Like MMP-7, this is a minimal domain MMP
missing the hemopexin-like C-terminus. This protease
seems to have a more limited substrate speciﬁcity com-
pared to MMP-7 and cannot degrade collagens, laminin and
elastin (Park et al. 2000). MMP-26 is unique among MMPs,
since it is the only MMP described so far that does not have
a functional cysteine switch mechanism to maintain the pro-
enzyme in its latent conformation. Loss of the cysteine
switch is attributed to the presence of a histidine residue
N-terminal to the cysteine, a feature that is only observed in
MMP-26 (Marchenko et al. 2001; Marchenko and Strongin
2001). Basal expression of MMP-26 is low except in
endometrium, but is increased in many carcinoma cell lines
(Marchenko et al. 2001). The physiological function of
MMP-26 remains to be elucidated.
Soluble MMPs: MMP-12 (macrophage metalloelastase)
MMP-12 was ﬁrst described in 1981 (Banda and Werb
1981) as murine metalloelastase and later identiﬁed as a
member of the MMP family (Shapiro et al. 1992). In 1993,
a human ortholog was found (Shapiro et al. 1993).
MMP-12 was identiﬁed as an elastolytic metalloprotease
produced by alveolar macrophages, which led to the trivial
name (murine) macrophage metalloelastase (MME) or
human macrophage elastase (HME). MMP-12 is expressed
as a 54-kDa inactive proenzyme and is activated to a
45-kDa active enzyme by removal of the propeptide
sequence. The mature enzyme can be further truncated to a
22-kDa active form on C-terminal processing mediated by
serine proteases or through autocatalytic cleavage (Shapiro
et al. 1993). Autocatalytic removal of the C-terminal
domain is possible in many other MMPs, but occurs very
slowly in contrast to MMP-12, which is readily processed
to the smaller form. Expression of MMP-12 is limited to
macrophages and is not observed in blood monocytes. As
the name reveals, a major substrate for MMP-12 is elastin,
but MMP-12 is capable of degrading other ECM constit-
uents (but not gelatin) (Banda et al. 1983) and many non-
matrix proteins in vitro (Chandler et al. 1996).
MMP-12 null mice show normal development in the
absence of inﬂammatory stress, but litter size is smaller,
presumably due to abnormalities of the placenta during
gestation. Macrophages obtained from knockout mice
retain only a small fraction of their elastolytic activity,
indicating that MMP-12 is indeed the most important
elastin-degrading enzyme (in mice). MMP-12 is necessary
for the penetration of macrophages through the basement
membrane, as demonstrated by a complete inhibition of
macrophage migration from MMP-12 null mice both in
vitro and in vivo (Shipley et al. 1996).
MMP-12 seems to play an intriguing role in cancer,
which is different from other MMPs. MMP-12 is the pri-
mary protease responsible for proteolytic liberation of
angiostatin from plasminogen. Angiostatin is a 38-kDa
protein with anti-angiogenic properties due to the selective
inhibition of endothelial cell proliferation. MMP-2 and -9
are also capable of degradation of plasminogen in vitro, but
were found to make only a minor or no contribution to the
production of angiostatin in an animal model (Dong et al.
1997; Houghton et al. 2006). This is another example of a
protective effect of MMP activity in tumor genesis, an
indication that knowledge of the actual biochemical
mechanism of the involvement of a protease in disease is
indispensable and cannot be replaced by mere association
of expression levels in tumors.
Since human MMP-12 was ﬁrst cloned from alveolar
macrophages, it is not surprising that the role of MMP-12
in lung disease has been extensively studied. The
involvement of MMP-12 in ﬁbrotic processes in the lung
is well established, but studies concerning the role of
MMP-12 in emphysema are diffuse due to species dif-
ferences between murine models and humans. In humans,
it was reported that MMP-12 is not upregulated in mac-
rophages of patients with emphysema compared to con-
trols, but rather that macrophage-derived MMP-9 and
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123MMP-1 are upregulated (Finlay et al. 1997). MMP-12, on
the other hand, was shown to be an absolute requirement
for the development of emphysema after cigarette smoke
exposure in a knockout animal model (Hautamaki et al.
1997; Matute-Bello et al. 2007, 2008). The interspecies
difference may have caused bias with respect to the
importance of MMP-12 since, although the failure of
MMP-12 null mice to develop emphysema upon smoke
exposure makes a more compelling point than determi-
nation of expression levels, MMP-12 seems to be the
major MMP in murine macrophages, while human mac-
rophages produce several MMPs (Parks and Shapiro
2001). Evidence for a role of MMP-12 in lung function is
based on a polymorphism in the MMP-12 gene that has
been described to have predictive value for lung function
decline in COPD (Joos et al. 2002), a ﬁnding that was
recently corroborated in a large association study between
a single nucleotide polymorphism (SNP) in the MMP-12
promotor, which decreases MMP-12 expression, and a
protective effect against lung function decline in asthma
and COPD patients (Hunninghake et al. 2009). Elevated
MMP-12 levels have been measured in induced sputum of
COPD patients (Demedts et al. 2006), while a recent
study has found only a slight increase of MMP-12 in
stage 0 of the disease (Ilumets et al. 2007). Proteolytic
fragments of elastin have been implicated as chemotactic
factors in macrophage recruitment (Senior et al. 1980),
giving a possible explanation for an early role of MMP-12
in emphysema development, with severe tissue destruc-
tion at later stages being mainly caused by other macro-
phage-derived proteases.
Conclusions
Matrix metalloproteases (MMPs) form a large family of
enzymes with broad substrate speciﬁcity. While their initial
role was mainly ascribed to turnover of the extracellular
matrix, this view must likely be revised based on recent,
more comprehensive studies. MMPs are involved in a del-
icate balance between proteolytic and anti-proteolytic
activity to conﬁne them in time and space. When this bal-
ance is disturbed, many disease phenotypes are observed
ranging from tissue destruction in chronic inﬂammatory
conditions, such as rheumatoid arthritis and COPD, to can-
cer metastasis and neurological disorders. The fact that
MMPs degrade proteins into fragments with often new,
completely different biological activities, supports the view
of protein species.
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